Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27715997 | 0.81 | KDM4E (0.36) | LMNASMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL1750195 | 0.77 | PARP1 (0.38) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL30637352 | 0.77 | NPSR1 (0.42) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL4138614 | 0.77 | NPSR1 (0.42) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL1490042 | 0.75 | MTOR (0.37) | PARP1LMNASMN1; SMN2MAPTDYRK1A | |
| SCHEMBL13074743 | 0.75 | PARP1 (0.37) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL22471636 | 0.75 | PARP1 (0.37) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL20606050 | 0.75 | LMNA (0.39) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL758549 | 0.75 | TP53 (0.37) | PARP1LMNASMN1; SMN2TLR9NPC1 | |
| SCHEMBL28312314 | 0.75 | PARP1 (0.37) | PARP1LMNASMN1; SMN2TLR9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009019518-A1 | PYRIMIDINE COMPOUNDS HAVING A FGFR INHIBITORY EFFECT | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | PARP1 2779/4885ENPP2 797/4885LMNA 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.